Study:
A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma
Rationale:
Drugs used in chemotherapy, such as carboplatin, paclitaxel, and cisplatin, work
in different ways to stop the growth of tumor cells, either by killing the cells or by
stopping them from dividing. Radiation therapy uses high-energy x-rays and other types of
radiation to kill tumor cells. Giving chemotherapy and radiation therapy after surgery may
kill any tumor cells that remain after surgery. It is not yet known whether carboplatin and
paclitaxel are more effective with or without cisplatin and radiation therapy in treating
patients with endometrial cancer.
Purpose:
This randomized phase III trial is studying carboplatin and paclitaxel to see how
well they work when given with or without cisplatin and radiation therapy in treating
patients with stage I, stage II, stage III, or stage IVA endometrial cancer.
Study Status: Recruiting
Recruiting:
Clinical Trials Office - Cleveland Clinic Cancer Center at Fai 216-476-9362
Clinical Trials Office - Cleveland Clinic Taussig Cancer Cente 866-223-8100
| Condition |
Intervention |
Phase |
|
Endometrial Cancer |
Drug: carboplatin
Drug: cisplatin
Drug: paclitaxel |
Phase 3 |
Verified by
Gynecologic Oncology Group
February, 2012
Sponsored by: Gynecologic Oncology Group
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT00942357
Study Type: Interventional
Study Design: Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment
Cleveland Clinic Cancer Center at Fairview Hospital
Cleveland, Ohio 44111
United States
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States
Daniela E. Matei, MD., Study Chair